Cargando…
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
BACKGROUND: A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators. OBJECTIVES: To evaluate the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733590/ https://www.ncbi.nlm.nih.gov/pubmed/35003104 http://dx.doi.org/10.3389/fimmu.2021.786554 |
_version_ | 1784627830938664960 |
---|---|
author | Xu, Qiu-Yan Xue, Jian-Hang Xiao, Yao Jia, Zhi-Juan Wu, Meng-Juan Liu, Yan-Yun Li, Wei-Li Liang, Xian-Ming Yang, Tian-Ci |
author_facet | Xu, Qiu-Yan Xue, Jian-Hang Xiao, Yao Jia, Zhi-Juan Wu, Meng-Juan Liu, Yan-Yun Li, Wei-Li Liang, Xian-Ming Yang, Tian-Ci |
author_sort | Xu, Qiu-Yan |
collection | PubMed |
description | BACKGROUND: A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators. OBJECTIVES: To evaluate the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies after vaccination and their predictive value for protection. METHODS: We determined the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) in 61 volunteers within 160 days after the CoronaVac vaccine. A logistic regression model was used to determine the predictors of the persistence of neutralizing antibody persistence. RESULTS: The seropositivity rates of neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA were only 4.92%, 27.87%, 21.31%, 3.28% and 0.00%, respectively, at the end of the first dose (28 days). After the second dose, the seropositivity rates reached peaks of 95.08%, 100.00%, 100.00%, 59.02% and 31.15% in two weeks (42 days). Their decay was obvious and the seropositivity rate remained at 19.67%, 54.10%, 50.82%, 3.28% and 0.00% on day 160, respectively. The level of neutralizing antibody reached a peak of 149.40 (101.00–244.60) IU/mL two weeks after the second dose (42 days) and dropped to 14.23 (7.62–30.73) IU/mL at 160 days, with a half-life of 35.61(95% CI, 32.68 to 39.12) days. Younger participants (≤31 years) had 6.179 times more persistent neutralizing antibodies than older participants (>31 years) (P<0.05). Participants with anti-Spike IgA seropositivity had 4.314 times greater persistence of neutralizing antibodies than participants without anti-Spike IgA seroconversion (P<0.05). CONCLUSIONS: Antibody response for the CoronaVac vaccine was intense and comprehensive with 95.08% neutralizing seropositivity rate, while decay was also obvious after 160 days. Therefore, booster doses should be considered in the vaccine strategies. |
format | Online Article Text |
id | pubmed-8733590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87335902022-01-07 Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days Xu, Qiu-Yan Xue, Jian-Hang Xiao, Yao Jia, Zhi-Juan Wu, Meng-Juan Liu, Yan-Yun Li, Wei-Li Liang, Xian-Ming Yang, Tian-Ci Front Immunol Immunology BACKGROUND: A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators. OBJECTIVES: To evaluate the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies after vaccination and their predictive value for protection. METHODS: We determined the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) in 61 volunteers within 160 days after the CoronaVac vaccine. A logistic regression model was used to determine the predictors of the persistence of neutralizing antibody persistence. RESULTS: The seropositivity rates of neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA were only 4.92%, 27.87%, 21.31%, 3.28% and 0.00%, respectively, at the end of the first dose (28 days). After the second dose, the seropositivity rates reached peaks of 95.08%, 100.00%, 100.00%, 59.02% and 31.15% in two weeks (42 days). Their decay was obvious and the seropositivity rate remained at 19.67%, 54.10%, 50.82%, 3.28% and 0.00% on day 160, respectively. The level of neutralizing antibody reached a peak of 149.40 (101.00–244.60) IU/mL two weeks after the second dose (42 days) and dropped to 14.23 (7.62–30.73) IU/mL at 160 days, with a half-life of 35.61(95% CI, 32.68 to 39.12) days. Younger participants (≤31 years) had 6.179 times more persistent neutralizing antibodies than older participants (>31 years) (P<0.05). Participants with anti-Spike IgA seropositivity had 4.314 times greater persistence of neutralizing antibodies than participants without anti-Spike IgA seroconversion (P<0.05). CONCLUSIONS: Antibody response for the CoronaVac vaccine was intense and comprehensive with 95.08% neutralizing seropositivity rate, while decay was also obvious after 160 days. Therefore, booster doses should be considered in the vaccine strategies. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8733590/ /pubmed/35003104 http://dx.doi.org/10.3389/fimmu.2021.786554 Text en Copyright © 2021 Xu, Xue, Xiao, Jia, Wu, Liu, Li, Liang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xu, Qiu-Yan Xue, Jian-Hang Xiao, Yao Jia, Zhi-Juan Wu, Meng-Juan Liu, Yan-Yun Li, Wei-Li Liang, Xian-Ming Yang, Tian-Ci Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title | Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title_full | Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title_fullStr | Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title_full_unstemmed | Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title_short | Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days |
title_sort | response and duration of serum anti-sars-cov-2 antibodies after inactivated vaccination within 160 days |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733590/ https://www.ncbi.nlm.nih.gov/pubmed/35003104 http://dx.doi.org/10.3389/fimmu.2021.786554 |
work_keys_str_mv | AT xuqiuyan responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT xuejianhang responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT xiaoyao responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT jiazhijuan responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT wumengjuan responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT liuyanyun responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT liweili responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT liangxianming responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days AT yangtianci responseanddurationofserumantisarscov2antibodiesafterinactivatedvaccinationwithin160days |